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Alpha-enolase: A novel cytosolic autoantigen in ANCA positive vascu-
litis. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from
patients with clinically proven vasculitis have been described as react-
ing with proteins present in the granules of human neutrophils. We have
studied sera from 59 ANCA positive patients to further characterize the
antibody response. In addition to the antigens previously identified in
the vasculitic syndromes (myeloperoxidase and serine proteinase 3) the
majority of these sera contained antibodies that reacted with a cytosolic
extract of neutrophils on Western blots. Nearly 40% of these sera had
antibodies directed against a cytosolic protein(s) of molecular mass 48
kD. This protein was purified from neutrophil cytosol by ammonium
sulphate fractionation, anion exchange and reverse phase chromatog-
raphy. Amino acid sequence analysis of a proteolytic fragment of this
protein identified it as a enolase. The anti-enolase antibodies only
recognized the a isoform and were present in sera giving either a
pANCA or cANCA staining pattern by indirect immunofluorescence.
Antibodies to a enolase were also found in sera from patients with
systemic lupus erythematosus, particularly those with renal disease.
We conclude that the antibody response in ANCA positive vasculitis is
not restricted to neutrophil granule proteins.
Until recently, the diagnosis of systemic vasculitis relied on
clinical criteria. With the discovery that autoantibodies against
human neutrophils were present in a high proportion of sera
from these patients, tests for the presence of circulating anti-
neutrophil cytoplasmic antibodies (ANCA) have proved to be
of diagnostic value [1—31. These autoantibodies are generally
detected by indirect immunofluorescence using ethanol-fixed
neutrophils as substrate. Two staining patterns are seen: cyto-
plasmic (cANCA) and perinuclear (pANCA) [4]. The majority
of sera showing a cANCA pattern contain antibodies directed
against serine proteinase 3 (SP3), a neutrophil granule protein
with a molecular weight of 29 kD [5—7]. The perinuclear staining
autoantibodies are directed predominantly against myeloperox-
idase (MPO) although lactoferrin and elastase have also been
reported as antigens [4, 8].
Target antigens other than granular proteins from the neutro-
phi! have been described but not characterized: for example,
antibodies against unidentified proteins in endothelial cells have
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been observed in ANCA-containing sera, although these are
neither specific nor diagnostic for vasculitis [9, 10]. Other
studies have reported that ANCA are directed against other
neutrophil proteins of unknown origin [11, 12]. At least some of
the autoantibodies appear to be against a primary granule
protein other than the more well-known antigens such as SP3,
MPO and elastase [12]. We have examined sera from 59 patients
with ANCA positive vasculitis and have found that they contain
autoantibodies that react with neutrophil cytosolic proteins. We
report the purification and identification of one of the more
common of these antigens.
Methods
Patients
Sera from 59 patients with a clinical diagnosis of vasculitis
and whose serum contained ANCA on indirect immunofluores-
cence were studied. All sera samples were from patients with
active, untreated disease. Of the 59 sera, 21 showed a pANCA
pattern [clinical diagnosis: 2 Wegeners granulomatosis (WG),
11 microscopic polyarteritis (MPA), 5 idiopathic crescentic
glomerulonephritis (ICGN), 3 others]. Thirty-eight sera showed
a cANCA pattern (clinical diagnosis: 21 WG, 12 MPA and 5
others). Sera from healthy blood donors were used as control
sera (N = 27). ANCA negative sera from patients with systemic
lupus erythematosus (SLE, N = 41), rheumatoid arthritis (RA,
N = 20), hemolytic uremic syndrome (HUS, N = 15), dermato-
myositis (N = 6), and scleroderma (N = 8) were used as disease
controls. SLE sera could be divided into two groups: those with
active lupus nephritis (N = 21), defined according to BILAG
scoring system [13] as patients having active urinary sediment
and proteinuria of > I glday, or renal biopsy showing active
nephritis in the last three months; or those without nephritis
(N = 20).
Detection of ANCA
ANCA were detected by indirect immunofluorescence [4].
Briefly, sera were diluted to 1/40 in PBS and incubated with
ethanol-fixed cytospin preparations of human neutrophils. An-
tibody binding was detected using fluorescein-conjugated sheep
anti-human immunoglobulin (Wellcome Diagnostics). In addi-
tion ANCA were sought using formalin fixed neutrophils [4].
This method allows easy differentiation of true ANCA which
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produces a typical granular cytoplasmic staining pattern while
antinuclear antibodies produce a nuclear pattern of staining.
Antibodies to MPO were measured by standard ELISA, using
MPO purified from primary granules by the method of Mathie-
son, Wong and Travis [14]. Briefly, MPO with a purity greater
than 98% (i.e. MPO having a ratio greater than 0.7 by A420:A280)
was coated onto Maxisorb ELISA plates (Flow Labs) at a
concentration of 1.5 gIml and serum samples were diluted to 1
in 100. Antibodies to SP3 were detected using a capture ELISA
after the method of Goldschmedding et al [5] using commer-
cially available monoclonal antibodies (anti-SP3 antibodies,
CLB-ANCA 12.8, Central Blood Transfusion Laboratories,
Amsterdam, The Netherlands). Both ELISAs were standard-
ized using Copenhagen standard sera containing cANCA or
pANCA antibodies [15]. In each ELISA positive sera were
taken as those with an OD greater than the mean 2 SD of 10
normal sera included in the same analysis.
Anti-nuclear antibodies
Anti-nuclear antibodies and anti-dsDNA antibodies were
detected using standard techniques using Hep2 cells and
Crithidiae Lucillae, respectively (Biodiagnostics Ltd.) as sub-
strate. A titer of >1/20 was regarded as positive.
Subcellular fractionation of neutrophils
Granulocytes were isolated from buffy coats obtained from
normal human volunteers using standard techniques and cy-
tosol prepared as described elsewhere [16, 17]. Briefly, purified
neutrophils were resuspended to a final concentration of 5 x 108
cells/ml in buffer (60 ms'i KCI, 6 mrvi PIPES, 1.8 mri NaC1, 2.1
mM MgC1, pH 7.3) and 6% sucrose (wt/wt) at 4°C with the
addition of protease inhibitors 1.0 mrvi dlisopropyl fluorophos-
phate (DFP), 10 g/ml Na-p-tosyl-L-Iysine chioro-methyl ke-
tone (TLCK), 10 /Lg/ml N-tosyl-L-phenylalanine chioromethyl
ketone (TPCK). Cells were disrupted by nitrogen cavitation (c
600 psi). A post-nuclear supernatant (PNS) was prepared by
centrifugation at 1400 g for 15 minutes at 4°C and cytosol was
isolated from the PNS by centrifugation on discontinuous
gradients of 15% and 34% sucrose (wt/wt in water) at 195,000 g
for 60 minutes at 4°C in a Kontron TST 41.14 swingout rotor.
Cytosol was recovered from above the 15% sucrose gradient
and granules were recovered in the pellets. A soluble extract of
the primary granule extract was prepared by resuspending the
granules in 0.2 M sodium acetate buffer pH 4.5 containing 0.5 M
NaCI [18] containing the same protease inhibitors. The suspen-
sion was then sonicated (3 x 30 seconds) before centrifugation
at 100,000 g for 30 minutes.
Gel electrophoresis and immunoblotting
SDS-PAGE was performed as described by Laemmli [19].
Prior to electrophoresis, samples were boiled in SDS sample
buffer (2% SDS, 0.06 M Tris, 0.004% bromophenol blue, 1%
sucrose, 10 mM EDTA and 0.1 M DTT) for three minutes before
separation on 12.5% polyacrylamide gels (Mini Protean II,
Biorad). For immunoblotting, samples were transferred to
nitrocellulose using a semi-dry blotting apparatus in transfer
buffer containing 25 mrt Tris, 192 mtvt glycine, 0.1% SDS and
10% (vol/vol) methanol, pH 8.3 at constant current of 0.8
mA/cm2 for 90 minutes. After transfer, filters were blocked in
1% gelatin, 3% bovine serum albumin (BSA), 10% goat serum,
0.05% Tween 20 for 60 minutes, then probed overnight at room
temperature with patient sera diluted 1:100 in blocking solution.
The primary antibodies were detected using goat anti-human
IgG conjugated to alkaline phosphatase (Promega PLC) and
color developed using the nitro blue tetrazolium, 5-Bromo-4-
chloro-3-indoyl phosphate reaction (Stratagene, California,
USA). Only clearly immunoreactive bands were accepted as
positive.
Protein purification
Fractions containing the 48 kD protein were identified by
immunoblotting of the samples with serum from a single patient
(Fig. 2B).
Ammonium sulphate fractionation. Solid ammonium sul-
phate was added sequentially to neutrophil cytosol (50 ml
containing 6 to 8 mg/ml protein) to 35%, 50%, 65% and 80%
saturation and the sample was stirred gently for two hours. The
precipitates were separated by centrifugation at 20,000 g for 10
minutes and resuspended in 5 ml of 15 m Tris/HCI, pH 8.0.
Ion exchange chromatography. Fractions containing the 48
kD protein were dialyzed against 15 mtvi Tris/HCI pH 8.0 at 4°C
and applied at a flow rate of 5.0 mI/hr to a column of DEAE-
Sepharose (FastFlow, 1 x 8 cm, Pharmacia) equilibrated in this
buffer. Fractions were monitored by absorbance at 280 nm and
the protein was located by Western blotting: a small volume of
each column fraction was precipitated by the addition of
trichloroacetic acid to a final concentration of 10%, then redis-
solved in SDS sample buffer and separated on gels containing
12.5% acrylamide. The protein failed to bind to the resin under
the above conditions.
HPLC. The protein was then made 0.1% in trifluoroacetic
acid (TFA) and 50 to 100 g samples were separated by
reverse-phase HPLC using a C4 column (Aquapore Butyl-300,
100 x 2.1 mm, Applied Biosystems). The column was equili-
brated in 0.1% TFA and the protein eluted with a linear gradient
of 0 to 60% acetonitrile containing 0.1% TFA at 0.5 mllmin.
Fractions were monitored by absorbance at 214 nm and were
dried under vacuum. The residues were redissolved in SDS
sample buffer and analyzed by SDS-PAGE and Western blot-
ting.
Protein sequencing
The band with the protein of interest was blotted onto
polyvinylidene difluoride (PVDF) membranes (Immobilon P,
Millipore) in 10 mrvi 3-Icyclohexylamino]- l-propanesulfonic
acid (CAPS) buffer, pH 11.0 containing 10% wt/vol MeOH [201.
Protein bands were stained with Coomassie Blue G-250 after
electroblotting. Automated Edman degradation was carried out
on the blotted protein using an Applied Biosystems Model 477A
pulsed-liquid sequencer, but the amino terminus was found to
be blocked. The purified protein was then cleaved by the
method of Cleveland et a! [21]. Protein from a single HPLC run
(@ 0.5 to 1.0 nmol) was resuspended in 50 d of 0.125 M
Tris/HC1 (pH 6.8) containing 0.1% SDS, 10% glycerol and
0.001% Bromophenol Blue and heated at 100°C for two min-
utes. S. aureus V8 proteinase (Sigma) was then added to a final
concentration of 12.5 jig/mI @ 8U/ml) and the sample was
incubated overnight at 37°C. The proteolytic fragments were
separated on 10% gels and blotted onto PVDF membranes [20]
from which they were excised for direct sequencing.
Moodie et a!: ANCA positive vasculitis 677
SP3 MPO SP3 + MPO Neither
Immunofluorescence
pattern
cANCA (N = 38) 28 3 1 6
pANCA (N = 21) — 12 4 5
Total 28 15 5 11
Western blots
Anti-enolase antibodies 10 6 3 3
Results
Of the 59 ANCA positive sera, 21 sera showed a pANCA
pattern and 38 sera showed a cANCA pattern. These sera were
examined by ELISA for the presence of antibodies against the
primary granule components SP3 and MPO. Results of ELISA
assays of these sera against the primary granule components
SP3 and MPO are summarized in Table 1. A small number of
patient sera which were ANCA positive by indirect immunoflu-
orescence did not react by ELISA with either SP3 or MPO.
These sera would therefore appear to have antibodies against
unidentified neutrophil constuents. Five of the sera contained
antibody to SP3 and MPO simultaneously.
In addition, antibodies directed against various cytosolic
proteins (prepared as described in the Methods, free from
granule contamination) could be detected in 45 of the 59 sera in
Western blotting: 31 of the cANCA sera and 14 of the pANCA
sera gave a positive reaction (data not shown). Representative
patterns of autoantibody reactivity against neutrophil cytosolic
proteins are shown in Figure 1. There was no apparent corre-
lation between the presence of autoantibodies giving a cANCA
or pANCA staining pattern by immunofluorescence and the
pattern of bands seen on Western blots with cytosol. The most
common antigen that patient sera reacted with appeared to have
a molecular mass of approximately 48 kD. A protein of this
mass was subsequently purified. A proportion of disease con-
trol sera were used to probe cytosol on Western blots: SLE N
= 41; hemolytic uremic syndrome N = 15; rheumatoid arthritis
N = 8; scieroderma N = 8; dermatomyositis N = 8; normal
healthy controls N = 10. Sera from 20 patients with SLE
produced a similar heterologous pattern of reaction with cyto-
solic proteins on Western blots, including that to the protein of
approximately 48 kD as seen in the predominant band in ANCA
positive sera (data not shown). There were no reactions seen on
cytosol in the other disease control groups.
Purfi cation and identification
Purification of the protein is shown in Figure 2. Most of the 48
kD antigen was located in the ammonium sulphate fraction
collected between 65 to 80% saturation. Unlike most of the
other proteins present in this fraction, the 48 kD antigen did not
bind to DEAE Sepharose at pH 8.0, providing a good purifica-
tion step. Final purification of the protein was achieved by
reverse phase HPLC (Fig. 2A). This resulted in a major band
staining for protein with Coomassie on SDS gels. Direct Se-
quencing of the intact protein was unsuccessful, indicating that
the protein was blocked at the N-terminus. Digestion of the
protein with S. aureus V8 proteinase produced several large
cleavage fragments with molecular weights of below 30 kD.
N-terminal sequence analysis of the highest molecular weight
fragment of 27 kD blotted onto PVDF gave the following 20
amino acid residues:
FMILPVGAANFREAMRIGAE
These corresponded exactly with residues 170-190 of the a
isoform of the glycolytic enzyme, enolase. The identity of the
protein was confirmed by reacting four of those sera giving a
strongly positive reaction with the 48 kD antigen purified from
human neutrophils and with a enolase purified from human
brain [22] (a gift from M. Duncan, Aberdeen, UK). This is
shown in Figure 3. The purified protein was also probed with a
mouse monoclonal antibody previously shown to recognize
both a and y human enolase (M. Duncan, personal communi-
cation). The monoclonal antibody reacted with the 48 kD
antigen purified from neutrophils (Fig. 3).
Vasculitis sera
When all of the sera from the ANCA positive patients were
tested against the 48 kD protein, 22 of 59 were found to give a
positive reaction with the protein on Western blots. None of the
ANCA positive sera were found to react with either the f3
isomer (rabbit; Sigma) or y isomer (human; a gift from Dr. I.N.
Day, Southampton University, UK) on Western blots. Eleven
of 21 sera with a P-ANCA and 12 of 38 sera with C-ANCA
staining by indirect immunofluorescence contained anti-enolase
antibodies (Table 1). Further comparison of the presence of
anti-enolase antibodies according to antibodies against the
granule proteins myeloperoxidase or serine protease 3 did not
show any significant correlation, although numbers were small
(Table 1). There was no correlation between the presence of
anti-enolase antibodies and ANCA titers measured by both
indirect immunofluorescence and ELISA, and no clinical dif-
ferences between sera from patients with and without anti-
enolase antibodies (data not shown).
Sera from all the patients with SLE (N = 41) contained
anti-nuclear antibodies, and of those patients with lupus nephri-
tis 17 of 21 sera contained anti-dsDNA antibodies. Sera from
one patient with lupus nephritis contained antibodies directed
against myeloperoxidase although this was of relatively low %
binding in ELISA (22% where positive titer >10%). Tests for
ANCA in other disease and healthy control sera were negative
by indirect immunofluorescence and by ELISA for SP3 and
MPO. Other autoantibody tests were not performed on these
sera.
Results of Western blots with control sera against a partially
purified preparation of a enolase are summarized in Table 2.
One out of 27 apparently healthy sera was found to give a
positive reaction with the protein. Patients with SLE, with and
without nephritis, were also reacted against the protein on
Western blots. Ten of the 41 patients with SLE also gave
positive results; of these eight sera were from patients with
clinical evidence of lupus nephritis (Table 2). The clinical,
serological and renal histological details of the lupus nephritis
patients both with and without anti-enolase antibodies are
Table 1. Sera from patients with vasculitis and positive for ANCA
by immunofluorescence were tested for the presence of antibodies
against SP3 using a capture ELISA and MPO using a standard
ELISA
The presence of anti-enolase antibodies detected by Western blotting
were compared with the presence of anti-MPO and anti-SP3 antibodies.
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Fig. 1. Immunoblots demonstrating the
heterogeneity of antigens in neutrophil cytosol
recognized by ANCA -positive sera. Cytosol
was isolated from of neutrophils; 20 jg
samples of protein were separated on 12.5%
SDS gels and probed in Western blots with a
variety of ANCA-positive sera. Lanes 1 to 6:
blots probed with cANCA sera. Lanes 7 to
12: blots probed with pANCA sera. Blots
marked with a C were probed with healthy
sera. Molecular weight markers (kD) are
indicated by the arrows.
summarized in Table 3. Disease control sera also reacted only
with the a isoform of enolase.
Discussion
ANCA (defined as antibodies detected by indirect immuno-
fluorescence on neutrophils) are commonly found in the sera of
patients with systemic vasculitis [1—41 and in a small minority of
patients with SLE and rheumatoid arthritis [8]. Several antigens
have been identified as the targets for ANCA associated with
systemic vasculitis: serine proteinase 3 in cANCA sera [5—7, 12,
23, 241 and myeloperoxidase, lactoferrin and neutrophil elastase
in pANCA sera [4, 7, 8, 201. Falk et al [9, 24] have also
described a C-ANCA staining pattern by antibodies directed
against a cationic antimicrobial protein with a molecular weight
of 57 kD (CAP57). These proteins are all basic and located in
the primary or secondary granules. Other studies have sug-
gested that the antibody response in vasculitis may be directed
against other unidentified antigens in neutrophil post-nuclear
supernatants [11].
In this study we have confirmed that there is heterogeneity of
the antibody response to neutrophils in vasculitis. Our results
show that, although most of the sera giving rise to a cANCA or
pANCA staining pattern on indirect immunofluorescence con-
tained antibodies against the classic antigens, SP3 and MPO (by
ELISA), a significant minority did not react with these proteins
indicating that they react with other granule proteins.
We have demonstrated for the first time the presence of
autoantibodies to cytosolic proteins in ANCA positive vasculi-
tis. Reactivity with a wide range of cytosolic proteins on
Western blots was found. We therefore selected the most
commonly reacting protein which was purified and identified by
amino acid sequence analysis as the ubiquitous glycolytic
enzyme, enolase. This is of particular interest in view of the
number of autoantigens which have recently been identified as
enzymes [25—29].
Enolase is a dimer composed of two equal subunits of
approximately 48 kD that are held together by Mg2. It exists as
three highly homologous isozymes, a, 13 and y, isozyme a is
found in most tissues, 13 in muscle and y is only in nervous
tissue [30, 31]. Despite the high degree of homology between
the isomers with approximately 83% homology between amino
acids [32—34], the antibodies in patient sera studied only reacted
with the a isomer, suggesting that these antibodies recognize a
unique epitope on this protein. Enolase may have functions
other than an enzymatic one. For example, HSP 48 in the yeast
S. cerevisiae is an isoform of enolase, possibly involved in
thermal tolerance [35].
Autoantibodies against enolase are unlikely to contribute to
the indirect immunofluorescence patterns on neutrophils
caused by ANCA, since a enolase is present in many cell types
which do not demonstrate a reaction with ANCA by immuno-
fluorescence. The apparent selectivity of the reaction of ANCA
with neutrophil granule proteins by immunofluorescence could
simply reflect the relative concentration of the various antigens.
The antigens that were originally described (MPO, SP3, elas-
tase and lactoferrin) are present at high concentration in the cell
as a whole (at approximately 1 to 5% of the total cellular
protein) [36] and are then packaged in even more concentrated
form in the granules. Abundant, concentrated granule proteins
would be much more likely to fix sufficient antibody for
visualization by immunofluorescence than more dispersed, di-
lute cytosolic proteins. Antibodies directed against other anti-
gens in both neutrophils and other cell types may be of
importance in the pathogenesis of the disease and yet not be
detected by indirect immunofluorescence.
Anti-enolase antibodies were found in a proportion of sera
from patients with ANCA positive vasculitis and with active
lupus nephritis. They were not found in a wide range of other
autoimmune disease controls, including hemolytic uremic syn-
drome (ANCA negative) where there is widespread vascular
injury. This might suggest that the presence of these antibodies
might have some diagnostic value, although sera from a wider
range of diseases will need to be studied to assess this possi-
bility. In addition, there were no clinical differences between
patients with vasculitis whose sera were positive or negative for
anti-enolase antibodies. There was no correlation between
antibodies directed against MPO or SP3 detected by ELISA or
by ANCA detected by immunofluorescence and the presence of
anti-enolase antibodies.
While ANCA are important in the diagnosis of the systemic
vasculitides, the relationship between the autoantibodies them-
selves and the pathogenesis of the disease is still not clear. Falk
et al have shown that ANCA induce a respiratory burst and
cause degranulation in neutrophils in vitro [381, suggesting that
these cells may induce vasculitis by release of free radicals and
degradative enzymes. Further evidence of a direct role of
ANCA has been suggested by the apparent restriction of the
immune response to neutrophil granule proteins and the fact
that ANCA titers often correlate with disease activity [38]. In
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contrast, we have shown that the antibody response is not
restricted to granule proteins, is directed against cytosolic
antigens and is heterogeneous. At feast one of these antigens
Fig. 2. PurfIcation of the 48 kD antigen. A.
Reverse-phase HPLC of the non-binding
fraction from the DEAE-Sepharose column.
The peak marked * coincided with the 48 kD
antigen shown in B. B. SDS-PAGE
Coomassie blue stained gel (lanes 1 to 4) and
corresponding Western blot (lanes 5 to 8)
showing successive purification of the 48 kD
antigen. (1 and 5) cytosol; (2 and 6) 65 to 80%
ammonium sulphate precipitate (3 and 7) non-
binding fraction from the DEAE column (4
and 8) peak marked * from the HPLC butyl
column.
(enolase) is widely distributed in other cell types. These findings
weaken the case for a restricted immune response to neutrophil
antigens and suggest that autoantibodies in vasculitis are more
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Table 3. Lupus nephritis: Clinical and histopathological details
Anti-enolase antibodies Present Absent
Bilag score
A 2 3
B 6 9
C 1
Renal histology by WHO grade
IVb 2 3
IVd 1
V 2
VI 3 3
Serology
ANA present 8 13
Anti-dsDNA antibody present 6 6
Total number 8 13
1 2 3 123
A B
Fig. 3. Isotype specificity of anti-enolase antibodies and vasculitis
sera. Western blot showing: (1) human y enolase; (2) human a enolase;
(3) the 48 kD antigen purified from human neutrophils probed (A) with
a monoclonal antibody that recognises both a and y enolase and (B)
with serum from a patient with ANCA positive vasculitis.
Table 2. Western blotting results against a enolase
N
Positive reaction
a enolase
Vasculitis
cANCA 38 12
pANCA 21 10
SLE
Nephritis 21 8
Non-nephritis 20 2
HUS 15 0
RA 20 1
Scieroderma 8 0
Dermatomyositis 6 0
Normal 27 1
Sera from patients with a variety of autoimmune diseases were tested
for the presence of antibodies to a enolase by Western blotting. N
indicates the number of samples from each group.
diverse as has been observed in SLE in which anti-enolase
antibodies were also observed.
The reason for autoantibody production in these conditions
remains to be determined. The immune response in vasculitis
could simply reflect tissue breakdown with the exposure of
otherwise hidden antigens to the immune system, although this
seems unlikely as neutrophil destruction and sequestration are
greater in many other conditions in which ANCA are not
observed [39]. Several mechanisms have been suggested
whereby intracellular autoantigens may be exposed to the
immune system. Proteins may be unusually expressed on the
cell surface particularly in inflammatory states [40], for example
p69 protein is expressed only on pancreatic B cells after
stimulation with gamma interferon. Antibodies formed against
BSA cross react with expressed p69 on human pancreatic B
cells. A recent study [41] has reported alpha enolase as a
plasminogen receptor and present as a functional extracellular
protein. Studies in other autoimmune diseases have demon-
strated that intracellular autoantigens may share epitopes with
infectious or other exogenous agents in genetically predisposed
individuals. In sera from patients with SLE antibodies directed
against the protein component of small nuclear ribonuclearpro-
teins snU1RNP also cross react with the p30gag protein of
mammalian C retrovirus, and a stretch of amino acid sequence
homology has been found [42]. Burroughs, Stermberg and
Baum [43] described a mechanism for molecular mimicry in
primary biliary cirrhosis where human autoantibodies in sus-
ceptible individuals were found to react with pyruvate dehydro-
genase as the result of a shared T cell epitope with "self'
peptides and E. co/i-derived peptide sequences. The association
of infection preceeding the onset of vasculitis is well described
[44], and there have been several reports of vasculitis being
treated successfully with antibiotics alone [45]. Whether the
autoantibody response is pathogenic will depend on many
factors, including the accessibility of antigen to effector mech-
anisms and the characteristics of the autoantibodies produced
such as epitope specificity, avidity, subclass and idiotype.
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